Menu

FDA to Cut Back Hiring of Non-US Citizens

The move appears to be out of step with other HHS agencies.

Aug 14, 2017
Shawna Williams

FDAHiring managers at the US Food and Drug Administration (FDA) will soon be unable to extend offers to non-citizens who have lived in the United States for fewer than three of the past five years, reports STAT. The policy, attributed to changes in the background check procedures needed to procure a government employee ID card, does not appear to be in line with policies at other federal science agencies, STAT finds.

A government policy on the ID cards, implemented in 2008, stipulates that applicants must have lived in the country for at least three of the preceding five years in order to complete the background check—but it also suggests that those who do not meet the requirement can be hired and use a different type of card until eligible.

An FDA document obtained by STAT states that the agency’s hiring change is due to a January 2017 update to that policy. Yet, “an HHS spokesman said the internal document did not include new policies on a residency requirement,” the outlet reports.

See “Scientists Concerned About Future of International Collaboration”

The order, expected to take effect October 1, will not apply to current employees. Nevertheless, two FDA staffers tell STAT they were “dismayed” and “stunned” by the policy change, and that it will affect “a huge chunk of the scientific workforce.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.